STRENSIQ

Brand name authorized in: Austria Brazil Canada Finland France Ireland Lithuania Netherlands Poland United Kingdom United States

Active ingredients

The drug STRENSIQ contains one active pharmaceutical ingredient (API):

1 Asfotase alfa
UNII Z633861EIM - ASFOTASE ALFA

Asfotase alfa, a human recombinant tissue-nonspecific alkaline phosphatase-Fc-deca-aspartate fusion protein with enzymatic activity, promotes mineralisation of the skeleton in patients with hypophosphatasia.

Read about Asfotase alfa

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
A16AB13
Asfotase alfa
A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB13

Medication package inserts

Below package inserts are available for further reading:

Title
Type
Country
STRENSIQ Solution for injection
Summary of Product Characteristics (SPC)

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
BR
Câmara de Regulação do Mercado de Medicamentos
Identifier(s): 565518120000201, 565518120000301, 565518120000401, 565518120000501
CA
Health Products and Food Branch
Identifier(s): 02444615, 02444623, 02444631, 02444658
FI
Lääkealan turvallisuus- ja kehittämiskeskus
Identifier(s): 035585, 071574, 183396, 586916
FR
Base de données publique des médicaments
Identifier(s): 64450234, 69258437
GB
Medicines & Healthcare Products Regulatory Agency
Identifier(s): 309303, 309306, 309309, 309315
LT
Valstybinė vaistų kontrolės tarnyba
Identifier(s): 1078436, 1078437, 1078438, 1078439, 1078440, 1078441, 1078442, 1078443, 1078444, 1078445
PL
Rejestru Produktów Leczniczych
Identifier(s): 100354166, 100354172
US
FDA, National Drug Code
Identifier(s): 25682-010, 25682-013, 25682-016, 25682-019